Accuracy of self-reported e-cigarette nicotine strength in young adults (18−26) and adults (27−54) who vape and differences in their preferences for nicotine strength and flavor.
Publication date: 1 November 2026 Source: Drug and Alcohol Dependence, Volume 288 Author(s): Julia Nowicka-Janik, Connor D. Martin, Michelle K. Page, Noel J. Leigh, Maciej L. Goniewicz
Accuracy of self-reported e-cigarette nicotine strength in young adults (18−26) and adults (27−54) who vape and differences in their preferences for nicotine strength and flavor. // Drug and Alcohol Dependence. – URL: https://www.sciencedirect.com/science/article/pii/S0376871626003704?dgcid=rss_sd_all
Accuracy of self-reported e-cigarette nicotine strength in young adults (18−26) and adults (27−54) who vape and differences in their preferences for nicotine strength and flavor. Drug and Alcohol Dependence. https://www.sciencedirect.com/science/article/pii/S0376871626003704?dgcid=rss_sd_all
“Accuracy of self-reported e-cigarette nicotine strength in young adults (18−26) and adults (27−54) who vape and differences in their preferences for nicotine strength and flavor.” Drug and Alcohol Dependence.
@article{article43497,
title = {Accuracy of self-reported e-cigarette nicotine strength in young adults (18−26) and adults (27−54) who vape and differences in their preferences for nicotine strength and flavor.},
journal = {Drug and Alcohol Dependence},
url = {https://www.sciencedirect.com/science/article/pii/S0376871626003704?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...